Subscribe
10 December 2024NewsAmericasMuireann Bolger

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders